Literature DB >> 34978590

A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience.

Rina Jiromaru1, Ryuji Yasumatsu2, Hidetaka Yamamoto3, Ryosuke Kuga1,3, Takahiro Hongo1,3, Takafumi Nakano4, Tomomi Manako1, Kazuki Hashimoto1, Takahiro Wakasaki1, Mioko Matsuo1, Takashi Nakagawa1.   

Abstract

PURPOSE: We herein report the treatment outcome of oropharyngeal squamous cell carcinoma (OPSCC) at Kyushu University Hospital, the total number of OPSCC cases, and changes in the proportion of human papilloma virus (HPV)-related carcinomas over time.
METHOD: We performed a retrospective analysis of 237 cases treated for OPSCC at Kyushu University Hospital between 2013 and 2019. We performed HPV-mRNA in situ hybridization and p16 immunohistochemistry. RESULT: This study included 197 males (82.1%) and 40 females (17.9%). The disease-specific, progression-free and overall survival (OS) were 69%, 62% and 61%, respectively, over the decade-long study period. p16-Immunohistochemistory and highrisk HPV mRNA in situ hybridization were positive in 114 (48.1%) and 105 (44.3%) cases, respectively. The number of HPV-related OPSCC cases increased according to an annual analysis. HPV+ cases had a significantly better prognosis than HPV- cases. In addition, p16+/HPV- cases had a significantly worse prognosis than p16+/HPV+ cases (OS: p = 0.0484). HPV+ OPSCC cases were associated with a younger age (< 60 years old) (p = 0.0429), non-smoker (p = 0.0001), lateral tumor site (< 0.00001), lymphoid metastasis (< 0.0001) and low clinical stage (< 0.0001).
CONCLUSION: The frequency of HPV-related OPSCC cases is increasing in Japan as well as worldwide, and such cases are characterized by no smoking habit, a young age, and a good prognosis. Even in p16+ OPSCC, HPV- cases had a poor prognosis, suggesting the importance of accurate HPV determination. To determine the intensity of treatment for HPV-related and non-related OPSCC, it is necessary to accumulate cases for the accurate HPV determination and comparison of treatment effects.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  HPV; Oropharyngeal squamous cell carcinoma; Prognosis

Mesh:

Substances:

Year:  2022        PMID: 34978590     DOI: 10.1007/s00405-021-07236-z

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  14 in total

1.  Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.

Authors:  Maura L Gillison; Andy M Trotti; Jonathan Harris; Avraham Eisbruch; Paul M Harari; David J Adelstein; Richard C K Jordan; Weiqiang Zhao; Erich M Sturgis; Barbara Burtness; John A Ridge; Jolie Ringash; James Galvin; Min Yao; Shlomo A Koyfman; Dukagjin M Blakaj; Mohammed A Razaq; A Dimitrios Colevas; Jonathan J Beitler; Christopher U Jones; Neal E Dunlap; Samantha A Seaward; Sharon Spencer; Thomas J Galloway; Jack Phan; James J Dignam; Quynh Thu Le
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

2.  Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists.

Authors:  James S Lewis; Beth Beadle; Justin A Bishop; Rebecca D Chernock; Carol Colasacco; Christina Lacchetti; Joel Todd Moncur; James W Rocco; Mary R Schwartz; Raja R Seethala; Nicole E Thomas; William H Westra; William C Faquin
Journal:  Arch Pathol Lab Med       Date:  2017-12-18       Impact factor: 5.534

3.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

4.  Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method.

Authors:  Justin A Bishop; Xiao-Jun Ma; Hongwei Wang; Yuling Luo; Peter B Illei; Shanaz Begum; Janis M Taube; Wayne M Koch; William H Westra
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

5.  Molecular subclassification determined by human papillomavirus and epidermal growth factor receptor status is associated with the prognosis of oropharyngeal squamous cell carcinoma.

Authors:  Takafumi Nakano; Hidetaka Yamamoto; Torahiko Nakashima; Toshimitsu Nishijima; Masanobu Satoh; Yui Hatanaka; Hideki Shiratsuchi; Ryuji Yasumatsu; Satoshi Toh; Shizuo Komune; Yoshinao Oda
Journal:  Hum Pathol       Date:  2015-11-17       Impact factor: 3.466

6.  Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment De-escalation trials.

Authors:  M M Rietbergen; R H Brakenhoff; E Bloemena; B I Witte; P J F Snijders; D A M Heideman; D Boon; S Koljenovic; R J Baatenburg-de Jong; C R Leemans
Journal:  Ann Oncol       Date:  2013-08-14       Impact factor: 32.976

7.  p16 overexpression and Rb loss correlate with high-risk HPV infection in oropharyngeal squamous cell carcinoma.

Authors:  Rina Jiromaru; Hidetaka Yamamoto; Ryuji Yasumatsu; Takahiro Hongo; Yui Nozaki; Takafumi Nakano; Kazuki Hashimoto; Takashi Nakagawa; Yoshinao Oda
Journal:  Histopathology       Date:  2021-05-06       Impact factor: 5.087

8.  Oropharyngeal Squamous Cell Carcinoma With Discordant p16 and HPV mRNA Results: Incidence and Characterization in a Large, Contemporary United States Cohort.

Authors:  Justin R Shinn; Seth J Davis; Krystle A Lang-Kuhs; Sarah Rohde; Xiaowei Wang; Ping Liu; William D Dupont; Dale Plummer; Wade L Thorstad; Rebecca D Chernock; Mitra Mehrad; James S Lewis
Journal:  Am J Surg Pathol       Date:  2021-07-01       Impact factor: 6.298

9.  Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Authors:  Hisham Mehanna; Max Robinson; Andrew Hartley; Anthony Kong; Bernadette Foran; Tessa Fulton-Lieuw; Matthew Dalby; Pankaj Mistry; Mehmet Sen; Lorcan O'Toole; Hoda Al Booz; Karen Dyker; Rafael Moleron; Stephen Whitaker; Sinead Brennan; Audrey Cook; Matthew Griffin; Eleanor Aynsley; Martin Rolles; Emma De Winton; Andrew Chan; Devraj Srinivasan; Ioanna Nixon; Joanne Grumett; C René Leemans; Jan Buter; Julia Henderson; Kevin Harrington; Christopher McConkey; Alastair Gray; Janet Dunn
Journal:  Lancet       Date:  2018-11-15       Impact factor: 79.321

10.  Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial.

Authors:  J B Vermorken; A Psyrri; R Mesía; F Peyrade; F Beier; B de Blas; I Celik; L Licitra
Journal:  Ann Oncol       Date:  2014-02-26       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.